Catalysts / IVVD
Upcoming FDA decisions and readouts we track for Invivyd, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Invivyd (IVVD, listed on Nasdaq). Both concern VYD2311 (COVID-19 prevention (monoclonal antibody); COVID-19 safety versus mRNA vaccine).
First on the list: the Phase 3 readout for VYD2311 (COVID-19 prevention (monoclonal antibody)), guided by the company to Q3 2026. By stage, the upcoming rows are 2 Phase 3 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Invivyd IVVD · Nasdaq | VYD2311 | COVID-19 prevention (monoclonal antibody) | Q3 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Invivyd IVVD · Nasdaq | VYD2311 | COVID-19 safety versus mRNA vaccine | Q3 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList